Preskorn SH - Search Results

1

How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.

Macaluso M, Nichols AI, Preskorn SH. Macaluso M, et al. Among authors: preskorn sh. Prim Care Companion CNS Disord. 2015 Mar 19;17(2):10.4088/PCC.14r01710. doi: 10.4088/PCC.14r01710. eCollection 2015. Prim Care Companion CNS Disord. 2015. PMID: 26445693 Free PMC article.

2

Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1.

Preskorn S, Flynn A, Macaluso M. Preskorn S, et al. J Psychiatr Pract. 2015 Sep;21(5):359-69. doi: 10.1097/PRA.0000000000000101. J Psychiatr Pract. 2015. PMID: 26348804 Review.

3

Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.

Macaluso M, Flynn A, Preskorn S. Macaluso M, et al. J Psychiatr Pract. 2016 May;22(3):203-20. doi: 10.1097/PRA.0000000000000157. J Psychiatr Pract. 2016. PMID: 27123800 Review.

4

Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.

Preskorn SH, Nichols AI, Paul J, Patroneva AL, Helzner EC, Guico-Pabia CJ. Preskorn SH, et al. J Psychiatr Pract. 2008 Nov;14(6):368-78. doi: 10.1097/01.pra.0000341891.43501.6b. J Psychiatr Pract. 2008. PMID: 19057238 Review.

5

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.

Nichols AI, Focht K, Jiang Q, Preskorn SH, Kane CP. Nichols AI, et al. Among authors: preskorn sh. Clin Drug Investig. 2011;31(3):155-67. doi: 10.2165/11586630-000000000-00000. Clin Drug Investig. 2011. PMID: 21288052 Clinical Trial.

6

How biomarkers will change psychiatry: from clinical trials to practice. Part I: introduction.

Macaluso M, Preskorn SH. Macaluso M, et al. Among authors: preskorn sh. J Psychiatr Pract. 2012 Mar;18(2):118-21. doi: 10.1097/01.pra.0000413277.11091.25. J Psychiatr Pract. 2012. PMID: 22418402 Review.

7

How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment.

Preskorn SH, Macaluso M, Trivedi M. Preskorn SH, et al. J Psychiatr Pract. 2015 Jul;21(4):267-74. doi: 10.1097/PRA.0000000000000082. J Psychiatr Pract. 2015. PMID: 26164052

8

Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.

Preskorn SH, Macaluso M. Preskorn SH, et al. J Psychiatr Pract. 2016 Mar;22(2):117-23. doi: 10.1097/PRA.0000000000000145. J Psychiatr Pract. 2016. PMID: 27138080

9

Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.

Preskorn SH, Kane CP, Lobello K, Nichols AI, Fayyad R, Buckley G, Focht K, Guico-Pabia CJ. Preskorn SH, et al. J Clin Psychiatry. 2013 Jun;74(6):614-21. doi: 10.4088/JCP.12m07807. Epub 2013 Mar 13. J Clin Psychiatry. 2013. PMID: 23541126 Clinical Trial.

10

Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.

Preskorn S, Patroneva A, Silman H, Jiang Q, Isler JA, Burczynski ME, Ahmed S, Paul J, Nichols AI. Preskorn S, et al. J Clin Psychopharmacol. 2009 Feb;29(1):39-43. doi: 10.1097/JCP.0b013e318192e4c1. J Clin Psychopharmacol. 2009. PMID: 19142106 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

346 results

Search Page

Filters